Strategic Innovation

Creating Solutions to Overcome Therapeutic Limitations in Healthcare


Novel Strategies to Maximize the Benefit of Drug Therapies

ImmunePrep™ and ChemoPrep™ are designed to optimize the targeted delivery of therapeutic antibodies and cancer chemotherapies. Whereas, ChemoPure™ reflects our vision for diminishing the toxicity of chemotherapy.

Our Company
$250 Billion

The size of the global market for therapeutic antibodies and cancer chemotherapies in 2022.*


*World Health Organization, Data Bridge Market Research

Sigyn Therapy in Action
Sigyn Therapy in Action

Targeting Unmet Needs in Global Health

We created Sigyn Therapy™ to address pathogen-associated inflammatory disorders that are not treatable with drug therapies. Candidate treatment indications include endotoxemia, drug-resistant bacterial and viral infections, community-acquired pneumonia and sepsis.

About Sigyn Therapy

Our Criterion for Strategic Innovation

"We create medical technologies with two attributes in mind:  they must offer to overcome a clearly-defined therapeutic limitation and if demonstrated to be effective, would provide a strategic competitive advantage within an established industry."

Jim Joyce
Chairman and CEO Inventor


Email Alerts

Stay informed and receive company updates straight to your inbox.

Sign up today

Stock Information